logo

BCAX

Bicara Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About BCAX

Bicara Therapeutics Inc.

A clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors

Pharmaceutical
12/12/2018
09/13/2024
NASDAQ Stock Exchange
55
12-31
Common stock
116 Huntington Avenue, Suite 703, Boston, MA 02116
--
Bicara Therapeutics Inc., was incorporated in Delaware on December 12, 2018. They are a clinical-stage biopharmaceutical company dedicated to bringing transformative bifunctional therapies to patients with solid tumors. Their main project, Alpha, is a bifunctional antibody that combines two clinically validated targets, epidermal growth factor receptor (EGFR) -directed monoclonal antibodies and a domain that binds human transforming growth factor β (TGF-b). Through this dual targeting mechanism, Alfa has the potential to exert powerful anti-tumor activity by simultaneously blocking the survival and proliferation of EGFR inherent in cancer cells, as well as immunosuppressive TGF-b signaling in the tumor microenvironment (TME). Ficerafusp alfa introduces TGF-b inhibitors directly into TME by binding to EGFR on tumor cells, which they believe will lead to a durable response and an increase in overall survival or OS, while reducing adverse reactions usually associated with systemic TGF-b inhibition.

Company Financials

EPS

BCAX has released its 2025 Q1 earnings. EPS was reported at -0.68, versus the expected -0.4, missing expectations. The chart below visualizes how BCAX has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime